I’ve asked a few different clinics to explain the difference between stem cells, exosomes, and PRP, and gotten a slightly different answer each time. That’s partly because the underlying biology is genuinely dense, and partly because “stem cells” has turned into a catch-all marketing word that doesn’t always describe what’s actually in the syringe. Before you sit down for a consultation, it’s worth knowing what these terms actually mean, since they carry pretty different implications for cost, for regulation, and for what you can realistically expect. A general resource like stem cell guide us is a decent place to start if you want to see how different clinics position each of these treatments before you start comparing quotes.
Mesenchymal stem cells
MSCs are adult stem cells usually harvested from bone marrow, fat tissue, or umbilical cord tissue, and the textbook explanation is that they can turn into other cell types like bone, cartilage, or fat. That part’s true, but it’s not really what most current treatment is banking on. What seems to matter more, at least for how MSCs are actually being used right now, is their ability to signal to the tissue around them. They release growth factors and other molecules that calm inflammation and can influence how blood vessels form in the area. It’s less about regrowing tissue from scratch and more about shifting what’s already happening inside a joint, and that signaling behavior is basically the mechanism behind everything that follows.
Exosomes
Cells, including MSCs, release tiny vesicles carrying proteins, lipids, and bits of genetic material like microRNA. Those vesicles are called exosomes, and they’re not cells themselves so much as the messages cells send to each other, one of the ways tissue coordinates its own behavior.
Exosome therapy pulls those vesicles out, typically from cultured MSCs, and uses them without the whole living cells attached. Because there’s nothing alive in the mix, the product is easier to store and there’s no chance of the cells proliferating unpredictably once they’re in you, which is part of why some clinics push it as a more consistent, standardized option. The counterargument is reasonable too. Clinical evidence for exosome therapy, especially outside of a hospital research setting, is still thinner than what exists for MSCs, and how different labs process and dose their product varies more than most patients realize. This is an area where the science is still catching up to the marketing.
PRP keeps getting lumped into this conversation, and it shouldn’t be
Platelet-rich plasma isn’t a stem cell product at all. It’s made from your own blood, drawn and spun down in a centrifuge to concentrate the platelets, then reinjected. Platelets release growth factors once activated, and that can support healing and calm inflammation in certain joint and tendon problems.
PRP also has a longer clinical track record than either MSC or exosome treatments, particularly for specific tendon injuries, though that doesn’t mean it’s automatically the stronger choice everywhere. It just means it’s been studied longer in a narrower set of applications, so the evidence looks different from the other two.
Why the mixed-up terminology actually costs patients money
Some clinics use these three words almost interchangeably in their marketing even though the biology, the regulation, and the price are all different. Ask about “stem cell treatment” for a bad knee and you might get quoted PRP, or an exosome product priced as if it were a full cell-based procedure. It’s not always deliberate; sometimes it’s just a front-desk staffer repeating whatever language is on the brochure. Either way, it makes comparing quotes across clinics genuinely hard unless you already know what to listen for, which is why it’s worth asking directly whether you’re being offered a whole-cell treatment or an acellular product, where the tissue is actually sourced from if it is cell-based, what evidence exists for that specific product in your specific condition rather than “regenerative medicine” as a broad category, and whether the processing is standardized from batch to batch.
So which one should you actually get
There isn’t a clean, universal answer, and anyone who hands you one without asking about your specific condition first is skipping a step they shouldn’t skip. These are three different tools with three different evidence bases, and which one makes sense depends entirely on what you’re actually treating. Reading up on exosome therapy specifically before your appointment is a reasonable way to spend an hour, and cross-checking what you learn against something like stem cell guide reviews adds a layer of outside verification. You’ll walk in able to tell the difference between a real answer and a rehearsed one
